While the markets reacted badly to the news Newron Pharmaceuticals SPA is to delay starting the pivotal program for its closely watched schizophrenia therapy evenamide, the Italian-headquartered drugmaker is confident that concerns raised by the US Food and Drug Administration over central nervous system events seen in animals can be allayed quickly.
No Panic At Newron Over Delayed Schizophrenia Drug Trial
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.
More from Neurological
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.